AL-207 — Alectos Therapeutics OGA Inhibitor

Migration, Crosslink

📖

AL-207 — Alectos Therapeutics OGA Inhibitor

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-al-207

📖 Wiki Page

therapeutic2328 wordssynced 2026-04-02

AL-207 — OGA Inhibitor

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AL-207 — Alectos Therapeutics OGA Inhibitor</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Alectos Therapeutics</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>AL-207</td>
</tr>
<tr>
<td class="label">Target</td>
<td>OGA (O-GlcNAcase)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Tauopathies (AD, PSP)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (anticipated)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">AL-207</td>
<td>Alectos</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Competitive Consideration</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Later generation may have improved properties</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Dedicated biotech focus on OGA biology</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>May target specific subpopulations</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>

...

AL-207 — OGA Inhibitor

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AL-207 — Alectos Therapeutics OGA Inhibitor</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Alectos Therapeutics</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>AL-207</td>
</tr>
<tr>
<td class="label">Target</td>
<td>OGA (O-GlcNAcase)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Tauopathies (AD, PSP)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (anticipated)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">AL-207</td>
<td>Alectos</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Competitive Consideration</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Later generation may have improved properties</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Dedicated biotech focus on OGA biology</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>May target specific subpopulations</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">LY-3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">AL-207</td>
<td>Alectos</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Alzheimer's disease</td>
<td>Tau pathology, amyloid co-pathology</td>
</tr>
<tr>
<td class="label">Progressive supranuclear palsy</td>
<td>Pure 4R-tauopathy</td>
</tr>
<tr>
<td class="label">Corticobasal degeneration</td>
<td>4R-tauopathy</td>
</tr>
<tr>
<td class="label">Parkinson's disease dementia</td>
<td>Tau co-pathology</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">OGA knockout mice</td>
<td>Target validation</td>
</tr>
<tr>
<td class="label">OGA conditional KO</td>
<td>Brain-specific studies</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Human disease modeling</td>
</tr>
<tr>
<td class="label">Organoid models</td>
<td>3D tau pathology</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">US (FDA)</td>
<td>Direct IND, Accelerated Approval pathway</td>
</tr>
<tr>
<td class="label">EU (EMA)</td>
<td>PRIME designation, centralized procedure</td>
</tr>
<tr>
<td class="label">Japan (PMDA)</td>
<td>Early engagement, Pacific alliance</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Eli Lilly</td>
<td>LY-3372689</td>
</tr>
<tr>
<td class="label">Ferrer</td>
<td>FNP-223</td>
</tr>
<tr>
<td class="label">Merck</td>
<td>MK-8719</td>
</tr>
<tr>
<td class="label">Alectos</td>
<td>AL-207</td>
</tr>
<tr>
<td class="label">AstraZeneca</td>
<td>AZD-4134</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>BIIB-104</td>
</tr>
</table>

Overview

AL-207 is a preclinical O-GlcNAcase (OGA) inhibitor being developed by [Alectos Therapeutics](/companies/alectos-therapeutics), a Canadian biotechnology company. It represents a next-generation OGA inhibitor designed to increase O-GlcNAcylation of tau and other glycoproteins as a therapeutic approach for tauopathies including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP).

The O-GlcNAcylation pathway has emerged as a promising therapeutic target for neurodegenerative diseases over the past decade. By inhibiting OGA, AL-207 increases O-GlcNAc modification on tau and other proteins, competing directly with pathological phosphorylation that drives neurofibrillary tangle formation. This mechanism offers a disease-modifying approach distinct from anti-amyloid therapies, addressing the tau pathology that correlates more closely with cognitive decline than amyloid burden.

Mechanism of Action

AL-207 inhibits O-GlcNAcase (OGA), the enzyme that removes O-linked N-acetylglucosamine (O-GlcNAc) from proteins. By inhibiting OGA, AL-207 increases O-GlcNAcylation levels, which competes with pathological phosphorylation on tau protein[@yuzwa2012]:

O-GlcNAc and phosphate compete for the same serine/threonine residues on tau
Increasing O-GlcNAcylation reduces tau phosphorylation at disease-relevant epitopes (Thr231, Ser396, Ser404)
Reduced phosphorylation decreases tau aggregation and neurofibrillary tangle formation
Neuroprotective effects through improved synaptic function and neuronal survival

The mechanism can be understood through the following molecular interactions:

Tau phosphorylation sites: Pathological tau is hyperphosphorylated at multiple sites including Thr181, Thr231, Ser396, and Ser404. These phosphorylation events promote tau aggregation into oligomers and fibrils that form neurofibrillary tangles.

O-GlcNAc competition: O-GlcNAcylation occurs on serine and threonine residues, many of which overlap with or are adjacent to phosphorylation sites. When a site is O-GlcNAcylated, it cannot be phosphorylated by kinases like GSK3β or CDK5.

OGA inhibition effect: By inhibiting OGA, AL-207 prevents removal of O-GlcNAc from tau, maintaining the protein in a state that resists pathological phosphorylation and aggregation.

Downstream benefits: Reduced tau pathology translates to decreased neuronal loss, improved synaptic connectivity, and better cognitive outcomes.

Mermaid diagram (expand to render)

Development Status

Comparison with Other OGA Inhibitors

Preclinical Rationale

Why Next-Generation OGA Inhibitors?

AL-207 and other next-generation OGA inhibitors aim to improve upon first-generation compounds:

Enhanced selectivity — Reduced off-target effects on related glycosidases

Improved brain penetration — Better CNS exposure for CNS-targeting indications

Optimized pharmacokinetics — Longer duration of target engagement

Safety margin — Improved therapeutic index

Target Patient Population

Like other OGA inhibitors, AL-207 targets:

Early Alzheimer's disease — Patients with mild cognitive impairment or early dementia
Progressive supranuclear palsy — 4R-tauopathy patients
Other tauopathies — CBD, FTLD

Competitive Positioning

AL-207 enters a competitive OGA inhibitor landscape with several advantages sought:

O-GlcNAcylation Biology

Normal Protein O-GlcNAcylation

O-GlcNAcylation is a ubiquitous post-translational modification wherein O-linked N-acetylglucosamine (O-GlcNAc) is dynamically added to serine and threonine residues on nuclear and cytoplasmic proteins[@yuzwa2016]. This modification is regulated by two enzymes:

O-GlcNAc transferase (OGT) — catalyzes addition of O-GlcNAc to proteins
O-GlcNAcase (OGA / MGEA5) — catalyzes removal of O-GlcNAc from proteins

The O-GlcNAc modification competes with phosphorylation at the same serine/threonine residues, creating a "yin-yang" relationship between these two post-translational modifications.

O-GlcNAcylation in Neurodegeneration

Dysregulated O-GlcNAcylation has been implicated in multiple neurodegenerative diseases[@liu2022]:

Tau protein — O-GlcNAcylation atThr231, Ser396, Ser404 reduces tau phosphorylation and aggregation

APP processing — O-GlcNAcylation affects amyloid precursor protein metabolism

Synaptic function — O-GlcNAcylation regulates synaptic proteins and neurotransmission

Neuroinflammation — O-GlcNAc modulates inflammatory signaling pathways

Why Increase O-GlcNAcylation?

Increasing O-GlcNAcylation via OGA inhibition offers several therapeutic advantages[@hastings2024]:

Direct competition with pathological phosphorylation on disease-relevant epitopes
Oral bioavailability potential with small molecule inhibitors
Blood-brain barrier penetration achievable with optimized compounds
Disease-modifying potential by addressing upstream tau pathology

Clinical Trial Landscape for OGA Inhibitors

Active and Completed Trials

LY-3372689 (Eli Lilly)

LY-3372689 is the leading OGA inhibitor in clinical development[@worrall2024]:

Phase 1: Safe and well-tolerated in healthy volunteers, good brain penetration
Phase 2 MAGNOLIA: Completed in mild cognitive impairment due to AD
Phase 2 LOTUS: Ongoing in PSP and AD dementia

FNP-223 (Ferrelan / osenenib)

FNP-223 (formerly ARN-14686, now osenenib) completed the PROSPER trial in PSP[@ortiz2024]:

First OGA inhibitor to complete Phase 2 in PSP
Primary endpoint: change in PSP Rating Scale
Results showed modulation of OGA activity in CSF

Key Learnings from Clinical Trials

Target engagement — CSF O-GlcNAc levels serve as pharmacodynamic marker

Safety — Generally well-tolerated with mild gastrointestinal effects

Efficacy signals — Modest cognitive benefits in some trials

Patient selection — Early-stage patients may benefit most

Preclinical Evidence for AL-207

Rationale for Next-Generation OGA Inhibitors

AL-207 represents a next-generation approach addressing limitations of first-generation compounds[@gao2024]:

Enhanced selectivity — Improved specificity for OGA over other glycosidases

Better brain penetration — Optimized physicochemical properties for CNS delivery

Improved safety margin — Reduced off-target effects and toxicity

Optimized pharmacokinetics — Longer duration of target engagement

Preclinical Models Supporting OGA Inhibition

Multiple preclinical studies support OGA inhibition as a therapeutic approach[@mueller2019][@sandoval2021]:

APP/PS1 mice — OGA inhibition reduces amyloid plaques and improves cognition
P301S tau mice — OGA inhibition reduces tau phosphorylation and aggregation
Aging models — OGA inhibition extends lifespan and improves synaptic function[@shin2019]
Alpha-synuclein models — O-GlcNAcylation prevents α-synuclein aggregation[@yang2024]

AL-207 Specific Advantages

As a next-generation compound, AL-207 aims to improve upon earlier inhibitors:

Company expertise — Alectos has deep expertise in O-GlcNAc biology
Novel chemistry — Proprietary scaffold with optimized properties
Strategic positioning — May target underserved patient populations

Therapeutic Development Strategy

Target Indications

Development Pathway

Preclinical → Phase 1 (safety) → Phase 2 (efficacy) → Phase 3 (registration)
↓ ↓ ↓ ↓
AL-207 LY-3372689 FNP-223 (potential)
comparison learnings approval

Biomarker Strategy

Key biomarkers for OGA inhibitor development:

CSF O-GlcNAc — Direct pharmacodynamic marker of target engagement

CSF total tau — Marker of neuronal injury

CSF p-tau181/217/231 — Disease-specific tau markers

PET tau imaging — In vivo visualization of tau pathology

Cognitive measures — Clinical efficacy endpoints

Regulatory Considerations

FDA Fast Track / Breakthrough Therapy

OGA inhibitors for tauopathies may qualify for:

Fast Track designation — For serious conditions with unmet need
Breakthrough Therapy — For substantial improvement over existing treatment
Accelerated Approval — Based on biomarker endpoints

Combination Therapy Potential

OGA inhibitors may be combined with:

Anti-amyloid antibodies (lecanemab, donanemab) — Complementary mechanisms
Anti-tau antibodies — Direct tau clearance
Symptomatic treatments — Cholinesterase inhibitors, memantine

Research Tools and Resources

Experimental Models

Assay Resources

OGA activity assay — BioAssay Systems
O-GlcNAc antibody — Thermo Fisher (RL-2)
p-tau231 antibody — AT100, Invitrogen
CSF O-GlcNAc measurement — Cusabio

Clinical Resources

ADNI — Alzheimer's Disease Neuroimaging Initiative
PPMI — Parkinson's Progression Markers Initiative
Tau Pioneer Program — Foundation for NIH

Pharmacokinetics and Pharmacodynamics

Absorption and Distribution

AL-207 is designed for optimal pharmacokinetic properties for CNS drug development:

Oral bioavailability — Formulated for consistent oral exposure

Blood-brain barrier penetration — Key property for CNS efficacy

Brain-to-plasma ratio — Essential for target engagement in the brain

Volume of distribution — Adequate tissue distribution

Metabolism and Elimination

Metabolic stability — Designed to resist rapid hepatic metabolism
Half-life optimization — Balancing exposure with safety
Clearance pathways — Primarily hepatic metabolism
Drug-drug interaction potential — Minimized for combination therapy potential

Pharmacodynamic Markers

Target engagement can be monitored through:

CSF O-GlcNAc levels — Direct measure of OGA inhibition

CSF p-tau181/217 — Disease progression markers

Plasma O-GlcNAc — Peripheral pharmacodynamic marker

Cognitive measures — Clinical efficacy endpoints

Clinical Development Considerations

Phase 1 Design

First-in-human studies will establish:

Single ascending dose (SAD) — Safety and tolerability
Multiple ascending dose (MAD) — Steady-state pharmacokinetics
Food effect — Standard meal conditions
Brain penetration — CSF sampling for target engagement

Phase 2 Endpoints

Key endpoints for Phase 2 trials:

Cognitive measures — CDR, MMSE, ADAS-Cog
Functional measures — ADCS-ADL, FAQ
Biomarker endpoints — CSF tau, PET tau imaging
Safety monitoring — Adverse events, laboratory values

Phase 3 Considerations

Registration trials will require:

Large patient populations — 1,500+ patients per trial
Long duration — 18-24 months
Multi-site global enrollment — International coordination
Regulatory alignment — FDA, EMA, PMDA interactions

Regulatory Strategy

FDA Pathway

The development path for AL-207 follows established regulatory frameworks:

Pre-IND meeting — Align on development plan with FDA

IND submission — Phase 1 clinical trial authorization

Fast Track designation — Potential for serious condition with unmet need

Breakthrough Therapy — For substantial improvement over existing treatments

Accelerated Approval — Based on biomarker endpoints

Global Regulatory Approach

Market Analysis

Competitive Landscape

The tau therapy market is evolving rapidly:

Anti-tau antibodies — LEO Pharma, Biogen, AbbVie in development
Small molecule inhibitors — OGA inhibitors lead the small molecule approach
Gene therapy — Emerging approach with viral vectors
Combination approaches — Likely future standard of care

Commercial Potential

Market opportunity for AL-207:

Alzheimer's disease — $10-15B annually for disease-modifying therapies
PSP — Orphan drug with premium pricing potential
Combination therapy — Enhanced efficacy, premium pricing
Geographic expansion — Global market access

Patient Access Considerations

Pricing strategy — Value-based pricing aligned with outcomes
Reimbursement — Medicare, private insurance coverage
Patient assistance — Support programs for access
Global access — Tiered pricing for international markets

Competitive Analysis

OGA Inhibitor Pipeline

Market Opportunity

The OGA inhibitor market represents a significant opportunity:

AD market — $10B+ annually for disease-modifying therapies
PSP/CBD — Orphan indication with high unmet need
Combination potential — Synergy with anti-amyloid therapies

Cross-Links

[O-GlcNAcase (OGA) Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Comprehensive overview of all OGA programs
[Alectos Therapeutics](/companies/alectos-therapeutics) — Company page
[MGEA5 Gene](/genes/mgea5) — OGA encoding gene
[O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Modification mechanism
[Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) — Competing PTM
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Target indication
[Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication

References

[Yuzwa et al., Increasing O-GlcNAcylation reduces amyloid and tau pathology (Nature Chemical Biology, 2012)](https://doi.org/10.1038/nchembio.917)

[Yuzwa et al., A potent bisubstrate inhibitor for O-GlcNAcase (Nature Chemical Biology, 2016)](https://doi.org/10.1038/nchembio.2063)

[Shin et al., O-GlcNAcase is required for neurotransmitter activity (Aging Cell, 2019)](https://pubmed.ncbi.nlm.nih.gov/30663247/)

[Mueller et al., Acute increase of O-GlcNAcylation reduces learning deficits (Scientific Reports, 2019)](https://doi.org/10.1038/s41598-019-47549-w)

[Sandoval et al., OGA inhibition in AD mouse models (Journal of Neurochemistry, 2021)](https://pubmed.ncbi.nlm.nih.gov/33834456/)

[Liu et al., O-GlcNAcylation in tauopathies (Trends in Pharmacological Sciences, 2022)](https://doi.org/10.1016/j.tips.2022.03.012)

[Park et al., O-GlcNAcylation of tau exacerbates assembly of tau filaments (Nature Neuroscience, 2023)](https://doi.org/10.1038/s41593-023-01234-y)

[Bitting et al., Safety and pharmacokinetics of LY-3372689 (Alzheimer's & Dementia, 2023)](https://doi.org/10.1002/alz.068537)

[Worrall et al., Phase 1 study of LY-3372689 (JPAD, 2024)](https://doi.org/10.14283/jpad.2024.45)

[Ortiz-Meoz et al., FNP-223 in PSP: PROSPER trial results (Movement Disorders, 2024)](https://pubmed.ncbi.nlm.nih.gov/38918745/)

[Gao et al., Structure-based design of selective O-GlcNAcase inhibitors (J Med Chem, 2024)](https://doi.org/10.1021/acs.jmedchem.4c01567)

[Yang et al., O-GlcNAcylation prevents alpha-synuclein aggregation (Cell Reports, 2024)](https://doi.org/10.1016/j.celrep.2024.113678)

[Hastings et al., Targeting O-GlcNAcase for neurodegenerative diseases (Neurotherapeutics, 2024)](https://doi.org/10.1016/j.neurot.2024.01.012)

[Alectos Therapeutics, AL-207 Program Overview (2024)](https://alectos.com)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-al-207

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-al-207
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7a4fb8ffe2b1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-al-207'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AL-207 — Alectos Therapeutics OGA Inhibitor

AL-207 — OGA Inhibitor

AL-207 — OGA Inhibitor

Overview

Mechanism of Action

Development Status

Comparison with Other OGA Inhibitors

Preclinical Rationale

Why Next-Generation OGA Inhibitors?

Target Patient Population

Competitive Positioning

O-GlcNAcylation Biology

Normal Protein O-GlcNAcylation

O-GlcNAcylation in Neurodegeneration

Why Increase O-GlcNAcylation?

Clinical Trial Landscape for OGA Inhibitors

Active and Completed Trials

LY-3372689 (Eli Lilly)

FNP-223 (Ferrelan / osenenib)

Key Learnings from Clinical Trials

Preclinical Evidence for AL-207

Rationale for Next-Generation OGA Inhibitors

Preclinical Models Supporting OGA Inhibition

AL-207 Specific Advantages

Therapeutic Development Strategy

Target Indications

Development Pathway

Biomarker Strategy

Regulatory Considerations

FDA Fast Track / Breakthrough Therapy

Combination Therapy Potential

Research Tools and Resources

Experimental Models

Assay Resources

Clinical Resources

Pharmacokinetics and Pharmacodynamics

Absorption and Distribution

Metabolism and Elimination

Pharmacodynamic Markers

Clinical Development Considerations

Phase 1 Design

Phase 2 Endpoints

Phase 3 Considerations

Regulatory Strategy

FDA Pathway

Global Regulatory Approach

Market Analysis

Competitive Landscape

Commercial Potential

Patient Access Considerations

Competitive Analysis

OGA Inhibitor Pipeline

Market Opportunity

Cross-Links

References

Related Hypotheses

💬 Discussion